© Reuters. Ad Com review Wednesday for Novo Nordisk’s semaglutide for T2D
- The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet on Wednesday, October 18 to review and discuss Novo Nordisk (CO:NOVOb)’s (NVO +4.4%) New Drug Application (NDA) seeking approval for once-weekly semaglutide as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
- FDA briefing doc
- Company briefing doc
- Now read: Roche Is Almost At The Finish Line